Viridian Therapeutics (Viridian Therapeutics) Price-to-Tangible-Book

: 3.28 (As of Today)

View and export this data going back to 2014. Start your Free Trial

As of today (2024-04-23), Viridian Therapeutics's share price is $14.30. Viridian Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.36. Hence, Viridian Therapeutics's Price to Tangible Book Ratio of today is 3.28.

The historical rank and industry rank for Viridian Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

VRDN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76 Med: 3.3 Max: 8.78
Current: 3.28

During the past 12 years, Viridian Therapeutics's highest Price to Tangible Book Ratio was 8.78. The lowest was 0.76. And the median was 3.30.

VRDN's Price-to-Tangible-Book is ranked worse than
58.48% of 1221 companies
in the Biotechnology industry
Industry Median: 2.67 vs VRDN: 3.28

A closely related ratio is called PB Ratio. As of today, Viridian Therapeutics's share price is $14.30. Viridian Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.36. Hence, Viridian Therapeutics's P/B Ratio of today is 3.28.

Viridian Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Viridian Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

1.06

8.78

4.77

4.99

Viridian Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book																4.77	5.08	5.73	4.51	4.99

Competitive Comparison

For the Biotechnology subindustry, Viridian Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Price-to-Tangible-Book falls into.

Viridian Therapeutics Price-to-Tangible-Book Calculation

Viridian Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	14.30	/	4.362
	=	3.28

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Viridian Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics (Viridian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (NAS:VRDN) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

1S1:Germany

Address

221 Crescent Street, Suite 401, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Executives

Stephen F. Mahoney	director, officer: President and CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	officer: Chief Operating Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sarah Gheuens	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Seth Harmon	officer: See Remarks	C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453
Lara Meisner	officer: General Counsel and Secretary	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453
Scott Dunseth Myers	director, officer: Chief Executive Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Jonathan Violin	officer: President and COO	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Barrett Katz	officer: Chief Medical Officer	6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301
Fairmount Healthcare Fund Gp Llc	director, other: See Remarks	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Carrie Melvin	officer: COO	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453
Frazier Life Sciences Public Fund, L.p.	10 percent owner	TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101
L.p. Fhmlsp,	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Fhmlsp, L.l.c.	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Kristian Humer	officer: CFO and CBO	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jennifer K. Moses	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709